Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Withdrawn3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated125%
withdrawn375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

NCT02224599
withdrawnphase_1

Consolidation Therapy in Patients With Hematologic Malignancies

NCT02709993
withdrawnphase_1

Consolidation Therapy in Patients With Metastatic Solid Malignancies

NCT02705703
withdrawnphase_1

Therapy for Progressive and/or Refractory Hematologic Malignancies

NCT02223312

Clinical Trials (4)

Showing 4 of 4 trials
NCT02224599Phase 1

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Terminated
NCT02709993Phase 1

Consolidation Therapy in Patients With Hematologic Malignancies

Withdrawn
NCT02705703Phase 1

Consolidation Therapy in Patients With Metastatic Solid Malignancies

Withdrawn
NCT02223312Phase 1

Therapy for Progressive and/or Refractory Hematologic Malignancies

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4